Dipartimento di Oncologia

Pubblicazioni

Tutti i miei prodotti della ricerca

Pubblicazioni selezionate

Martinelli, Erika, Troiani, Teresa, Sforza, Vincenzo, Martini, Giulia, Cardone, Claudia, Vitiello, Pietro Paolo, Ciardiello, Davide, Rachiglio, Anna Maria, Normanno, Nicola, Sartore-Bianchi, Andrea, Marsoni, Silvia, Bardelli, Alberto, Siena, Salvatore, Ciardiello, Fortunato (2018)
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
https://iris.unito.it/handle/2318/1660169

Montagut, Clara, Argilés, Guillem, Ciardiello, Fortunato, Poulsen, Thomas T, Dienstmann, Rodrigo, Kragh, Michael, Kopetz, Scott, Lindsted, Trine, Ding, Cliff, Vidal, Joana, Clausell-Tormos, Jenifer, Siravegna, Giulia, Sánchez-Martín, Francisco J, Koefoed, Klaus, Pedersen, Mikkel W, Grandal, Michael M, Dvorkin, Mikhail, Wyrwicz, Lucjan, Rovira, Ana, Cubillo, Antonio, Salazar, Ramon, Desseigne, Françoise, Nadal, Cristina, Albanell, Joan, Zagonel, Vittorina, Siena, Salvatore, Fumi, Guglielmo, Rospo, Giuseppe, Nadler, Paul, Horak, Ivan D, Bardelli, Alberto, Tabernero, Josep (2018)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
https://iris.unito.it/handle/2318/1660159

Siena, S , Sartore-Bianchi, A , Garcia-Carbonero, R , Karthaus, M , Smith, D , Tabernero, J , Van Cutsem, E , Guan, X , Boedigheimer, M , Ang, A , Twomey, B , Bach, B A , Jung, A S , Bardelli, A (2018)
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1660171

Siena, S, Sartore-Bianchi, A, Marsoni, S, Hurwitz, H I, McCall, S J, Penault-Llorca, F, Srock, S, Bardelli, A, Trusolino, L (2018)
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
https://iris.unito.it/handle/2318/1667463

Carbone, Carmine, Piro, Geny, Simionato, Francesca, Ligorio, Francesca, Cremolini, Chiara, Loupakis, Fotios, Alì, Greta, Rossini, Daniele, Merz, Valeria, Santoro, Raffaela, Zecchetto, Camilla, Zanotto, Marco, Di Nicolantonio, Federica, Bardelli, Alberto, Fontanini, Gabriella, Tortora, Giampaolo, Melisi, Davide (2017)
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients.
https://iris.unito.it/handle/2318/1634256

Siravegna, Giulia, Marsoni, Silvia, Siena, Salvatore, Bardelli, Alberto (2017)
Integrating liquid biopsies into the management of cancer.
https://iris.unito.it/handle/2318/1635464

Bradley, Conor A, Salto-Tellez, Manuel, Laurent-Puig, Pierre, Bardelli, Alberto, Rolfo, Christian, Tabernero, Josep, Khawaja, Hajrah A , Lawler, Mark, Johnston, Patrick G , Schaeybroeck, Sandra Van (2017)
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
https://iris.unito.it/handle/2318/1635364

Picco, Gabriele, Petti, Consalvo, Centonze, Alessia, Torchiaro, Erica, Crisafulli, Giovanni, Novara, Luca, Acquaviva, Andrea, Bardelli, Alberto, Medico, Enzo (2017)
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions.
https://iris.unito.it/handle/2318/1635452

Bardelli, Alberto, Pantel, Klaus (2017)
Liquid Biopsies, What We Do Not Know (Yet).
https://iris.unito.it/handle/2318/1635377

Venesio, Tiziana, Siravegna, Giulia, Bardelli, Alberto, Sapino, Anna (2017)
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
https://iris.unito.it/handle/2318/1647541

Fujii, Takeo, Barzi, Afsaneh, Sartore-Bianchi, Andrea, Cassingena, Andrea, Siravegna, Giulia, Karp, Daniel D , Piha-Paul, Sarina A , Subbiah, Vivek, Tsimberidou, Apostolia M , Huang, Helen J , Veronese, Silvio, Di Nicolantonio, Federica, Pingle, Sandeep, Vibat, Cecile Rose T , Hancock, Saege, Berz, David, Melnikova, Vladislava O , Erlander, Mark G , Luthra, Rajyalakshmi, Kopetz, E Scott, Meric-Bernstam, Funda, Siena, Salvatore, Lenz, Heinz-Josef, Bardelli, Alberto, Janku, Filip (2017)
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers.
https://iris.unito.it/handle/2318/1647298

Rospo, Giuseppe, Corti, Giorgio, Crisafulli, Giovanni, Novara, Luca, Bardelli, Alberto (2017)
Tracking colorectal cancer evolution in time and space.
https://iris.unito.it/handle/2318/1651436

Picco, Gabriele, Petti, Consalvo, Sassi, Francesco, Grillone, Katia, Migliardi, Giorgia, Rossi, Teresa, Isella, Claudio, Di Nicolantonio, Federica, Sarotto, Ivana, Sapino, Anna, Bardelli, Alberto, Trusolino, Livio, Bertotti, Andrea, Medico, Enzo (2017)
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.
https://iris.unito.it/handle/2318/1618636

Sartore-Bianchi, A, Pietrantonio, F, Amatu, A, Milione, M, Cassingena, A, Ghezzi, S, Caporale, M, Berenato, R, Falcomatà, C, Pellegrinelli, A, Bardelli, A, Nichelatti, M, Tosi, F, De Braud, F, Di Nicolantonio, F, Barault, L, Siena, S, co-last and corresponding author, (2017)
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
https://iris.unito.it/handle/2318/1622763

Oddo, D, Siravegna, G, Gloghini, A, Vernieri, C, Mussolin, B, Morano, F, Crisafulli, G, Berenato, R, Corti, G, Volpi, Cc, Buscarino, M, Niger, M, Dunne, Pd, Rospo, G, Valtorta, E, Bartolini, A, Fucà, G, Lamba, S, Martinetti, A, Di Bartolomeo, M, de Braud, F, Bardelli, A, Pietrantonio, F, Di Nicolantonio, F (2017)
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
https://iris.unito.it/handle/2318/1647300

Barault, L, Amatu, A, Siravegna, G, Ponzetti, A, Moran, S, Cassingena, A, Mussolin, B, Falcomatà, C, Binder, Am, Cristiano, C, Oddo, D, Guarrera, S, Cancelliere, C, Bustreo, S, Bencardino, K, Maden, S, Vanzati, A, Zavattari, P, Matullo, G, Truini, M, Grady, Wm, Racca, P, Michels, Kb, Siena, S, Esteller, M, Bardelli, A, Sartore-Bianchi, A, Di Nicolantonio, F (2017)
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1650175

Siravegna, Giulia, Geuna, Elena, Mussolin, Benedetta, Crisafulli, Giovanni, Bartolini, Alice, Galizia, Danilo, Casorzo, Laura, Sarotto, Ivana, Scaltriti, Maurizio, Sapino, Anna, Bardelli, Alberto, Montemurro, Filippo (2017)
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.
https://iris.unito.it/handle/2318/1660209

Germano, Giovanni, Lamba, Simona, Rospo, Giuseppe, Barault, Ludovic, Magri, Alessandro, Maione, Federica, Russo, Mariangela, Crisafulli, Giovanni, Bartolini, Alice, Lerda, Giulia, Siravegna, Giulia, Mussolin, Benedetta, Frapolli, Roberta, Montone, Monica, Morano, Federica, De Braud, Filippo, Amirouchene-Angelozzi, Nabil, Marsoni, Silvia, D', Incalci, Maurizio, Orlandi, Armando, Giraudo, Enrico, Sartore-Bianchi, Andrea, Siena, Salvatore, Pietrantonio, Filippo, Di Nicolantonio, Federica, Bardelli, Alberto (2017)
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
https://iris.unito.it/handle/2318/1660203

Siravegna, G, Sartore-Bianchi, A, Mussolin, B, Cassingena, A, Amatu, A, Novara, L, Buscarino, M, Corti, G, Crisafulli, G, Bartolini, A, Tosi, F, Erlander, M, Di Nicolantonio, F, Siena, S, Bardelli, A (2017)
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
https://iris.unito.it/handle/2318/1634243

Ali, Moiez, Kaltenbrun, Erin, Anderson, Grace R , Stephens, Sarah Jo, Arena, Sabrina, Bardelli, Alberto, Counter, Christopher M , Wood, Kris C * (2017)
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
https://iris.unito.it/handle/2318/1660863

Amirouchene-Angelozzi, Nabil, Swanton, Charles, Bardelli, Alberto (2017)
Tumor evolution as a therapeutic target.
https://iris.unito.it/handle/2318/1660860

Bardelli, Alberto (2017)
Medical research: Personalized test tracks cancer relapse.
https://iris.unito.it/handle/2318/1660892

Pietrantonio, Filippo*, Di Nicolantonio, Federica*, Schrock, Alexa B, Lee, Jeeyun, Tejpar, Sabine, Sartore-Bianchi, Andrea, Hechtman, Jaclyn F, Christiansen, Jason, Novara, Luca, Tebbutt, Niall, Fucà, Giovanni, Antoniotti, Carlotta, Kim, Seung Tae, Murphy, Danielle, Berenato, Rosa, Morano, Federica, Sun, James, Min, Bosun, Stephens, Philip J, Chen, Marissa, Lazzari, Luca, Miller, Vincent A, Shoemaker, Robert, Amatu, Alessio, Milione, Massimo, Ross, Jeffrey S, Siena, Salvatore, Bardelli, Alberto, Ali, Siraj M, Falcone, Alfredo, de Braud, Filippo, Cremolini, Chiara, *corresponding authors (2017)
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
https://iris.unito.it/handle/2318/1660682

Fujii, Takeo, Barzi, Afsaneh, Sartore-bianchi, Andrea, Cassingena, Andrea, Siravegna, Giulia, Karp, Daniel, Piha-paul, Sarina, Subbiah, Vivek, Tsimberidou, Apostolia M, Huang, Helen, Veronese, Sillvio, DI NICOLANTONIO, Federica, Pingle, Sandeep C, Vibat, Cecile Rose T, Hancock, Saege, Berz, David, Melnikova, Vladislava O, Erlander, Mark G, Luthra, Rajyalakshmi, Kopetz, Scott, Meric-bernstam, Funda, Siena, Salvatore, Lenz, Heinz-josef, Bardelli, Alberto, Janku, Filip (2017)
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.
https://iris.unito.it/handle/2318/1651437

Amatu, A, Barault, L, Moutinho, C, Cassingena, A, Bencardino, K, Ghezzi, S, Palmeri, L, Bonazzina, E, Tosi, F, Ricotta, R, Cipani, T, Crivori, P, Gatto, R, Chirico, G, Marrapese, G, Truini, M, Bardelli, A, Esteller, M, Di Nicolantonio, F, Sartore-Bianchi, A, Siena, S (2016)
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1569776

Arena, Sabrina, Siravegna, Giulia, Mussolin, Benedetta, Kearns, Jeffrey D , Wolf, Beni B , Misale, Sandra, Lazzari, Luca, Bertotti, Andrea, Trusolino, Livio, Adjei, Alex A , Montagut, Clara, Di Nicolantonio, Federica, Nering, Rachel, Bardelli, Alberto (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
https://iris.unito.it/handle/2318/1559473

Sartore-Bianchi, Andrea, Trusolino, Livio*, Martino, Cosimo, Bencardino, Katia, Lonardi, Sara, Bergamo, Francesca, Zagonel, Vittorina, Leone, Francesco, Depetris, Ilaria, Martinelli, Erika, Troiani, Teresa, Ciardiello, Fortunato, Racca, Patrizia, Bertotti, Andrea, Siravegna, Giulia, Torri, Valter, Amatu, Alessio, Ghezzi, Silvia, Marrapese, Giovanna, Palmeri, Laura, Valtorta, Emanuele, Cassingena, Andrea, Lauricella, Calogero, Vanzulli, Angelo, Regge, Daniele, Veronese, Silvio, Comoglio, Paolo M , Bardelli, Alberto*, Marsoni, Silvia*, Siena, Salvatore* (*Co-Senior Authors) (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial.
https://iris.unito.it/handle/2318/1560696

Siravegna, Giulia, Bardelli, Alberto (2016)
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.
https://iris.unito.it/handle/2318/1613072

Hata, Aaron N, Niederst, Matthew J, Archibald, Hannah L, Gomez-Caraballo, Maria, Siddiqui, Faria M, Mulvey, Hillary E, Maruvka, Yosef E, Ji, Fei, Bhang, Hyo-Eun C, Krishnamurthy Radhakrishna, Viveksagar, Siravegna, Giulia, Hu, Haichuan, Raoof, Sana, Lockerman, Elizabeth, Kalsy, Anuj, Lee, Dana, Keating, Celina L, Ruddy, David A, Damon, Leah J, Crystal, Adam S, Costa, Carlotta, Piotrowska, Zofia, Bardelli, Alberto, Iafrate, Anthony J, Sadreyev, Ruslan I, Stegmeier, Frank, Getz, Gad, Sequist, Lecia V, Faber, Anthony C, Engelman, Jeffrey A (2016)
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
https://iris.unito.it/handle/2318/1613071

Pietrantonio, Filippo, Vernieri, Claudio, Siravegna, Giulia, Mennitto, Alessia, Berenato, Rosa, Perrone, Federica, Gloghini, Annunziata, Tamborini, Elena, Lonardi, Sara, Morano, Federica, Picciani, Benedetta, Busico, Adele, Volpi, Chiara C, Martinetti, Antonia, Battaglin, Francesca, Bossi, Ilaria, Pellegrinelli, Alessio, Milione, Massimo, Cremolini, Chiara, Di Bartolomeo, Maria, Bardelli, Alberto, de Braud, Filippo (2016)
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1622760

Sartore-Bianchi, Andrea, Valtorta, Emanuele, Amatu, Alessio, Veronese, Silvio, Lauricella, Calogero, Bonazzina, Erica, Siravegna, Giulia, Truini, Mauro, Bardelli, Alberto, Siena, Salvatore (2016)
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1622758

Pozzi, Chiara, Cuomo, Alessandro, Spadoni, Ilaria, Magni, Elena, Silvola, Alessio, Conte, Alexia, Sigismund, Sara, Ravenda, Paola Simona, Bonaldi, Tiziana, Zampino, Maria Giulia, Cancelliere, Carlotta, Di Fiore, Pier Paolo, Bardelli, Alberto, Penna, Giuseppe, Rescigno, Maria (2016)
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
https://iris.unito.it/handle/2318/1622748

Van Cutsem, E, Cervantes, A, Adam, R, Sobrero, A, Van Krieken, J H, Aderka, D, Aranda Aguilar, E, Bardelli, A, Benson, A, Bodoky, G, Ciardiello, F, D', Hoore, A, Diaz-Rubio, E, Douillard, J-Y, Ducreux, M, Falcone, A, Grothey, A, Gruenberger, T, Haustermans, K, Heinemann, V, Hoff, P, Köhne, C-H, Labianca, R, Laurent-Puig, P, Ma, B, Maughan, T, Muro, K, Normanno, N, Österlund, P, Oyen, W J G, Papamichael, D, Pentheroudakis, G, Pfeiffer, P, Price, T J, Punt, C, Ricke, J, Roth, A, Salazar, R, Scheithauer, W, Schmoll, H J, Tabernero, J, Taïeb, J, Tejpar, S, Wasan, H, Yoshino, T, Zaanan, A, Arnold, D (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1622753

Van Emburgh, Beth O, Arena, Sabrina, Siravegna, Giulia, Lazzari, Luca, Crisafulli, Giovanni, Corti, Giorgio, Mussolin, Benedetta, Baldi, Federica, Buscarino, Michela, Bartolini, Alice, Valtorta, Emanuele, Vidal, Joana, Bellosillo, Beatriz, Germano, Giovanni, Pietrantonio, Filippo, Ponzetti, Agostino, Albanell, Joan, Siena, Salvatore, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Montagut, Clara, Bardelli, Alberto (2016)
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
https://iris.unito.it/handle/2318/1621186

Goyal, Lipika, Saha, Supriya K, Liu, Leah Y, Siravegna, Giulia, Leshchiner, Ignaty, Ahronian, Leanne G, Lennerz, Jochen K, Vu, Phuong, Deshpande, Vikram, Kambadakone, Avinash, Mussolin, Benedetta, Reyes, Stephanie, Henderson, Laura, Sun, Jiaoyuan Elisabeth, Van Seventer, Emily E, Gurski, Joseph M, Baltschukat, Sabrina, Schacher-Engstler, Barbara, Barys, Louise, Stamm, Christelle, Furet, Pascal, Ryan, David P, Stone, James R, Iafrate, A John, Getz, Gad, Graus Porta, Diana, Tiedt, Ralph, Bardelli, Alberto, Juric, Dejan, Corcoran, Ryan B, Bardeesy, Nabeel, Zhu, Andrew X (2016)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
https://iris.unito.it/handle/2318/1622762

Swanton, C, Soria, J-C, Bardelli, A, Biankin, A, Caldas, C, Chandarlapaty, S, de Koning, L, Dive, C, Feunteun, J, Leung, S-Y, Marais, R, Mardis, E R, Mcgranahan, N, Middleton, G, Quezada, S A, Rodón, J, Rosenfeld, N, Sotiriou, C, André, F (2016)
Consensus on precision medicine for metastatic cancers: a report from the MAP conference.
https://iris.unito.it/handle/2318/1621180

Pietrantonio, Filippo, Oddo, Daniele, Gloghini, Annunziata, Valtorta, Emanuele, Berenato, Rosa, Barault, Ludovic, Caporale, Marta, Busico, Adele, Morano, Federica, Gualeni, Ambra Vittoria, Alessi, Alessandra, Siravegna, Giulia, Perrone, Federica, Di Bartolomeo, Maria, Bardelli, Alberto, de Braud, Filippo, Di Nicolantonio, Federica (2016)
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer.
https://iris.unito.it/handle/2318/1591711

Sánchez-Martín, Francisco J , Bellosillo, Beatriz, Gelabert-Baldrich, Mariona, Dalmases, Alba, Cañadas, Israel, Vidal, Joana, Martinez, Alejandro, Argilés, Guillem, Siravegna, Giulia, Arena, Sabrina, Koefoed, Klaus, Visa, Laura, Arpí, Oriol, Horak, Ivan David, Iglesias, Mar, Stroh, Christopher, Kragh, Michael, Rovira, Ana, Albanell, Joan, Tabernero, Josep, Bardelli, Alberto, Montagut, Clara (2016)
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer.
https://iris.unito.it/handle/2318/1613075

Russo, Mariangela, Misale, Sandra, Wei, Ge, Siravegna, Giulia, Crisafulli, Giovanni, Lazzari, Luca, Corti, Giorgio, Rospo, Giuseppe, Novara, Luca, Mussolin, Benedetta, Bartolini, Alice, Cam, Nicholas, Patel, Roopal, Yan, Shunqi, Shoemaker, Robert, Wild, Robert, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Li, Gang, Siena, Salvatore, Bardelli, Alberto (2016)
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer.
https://iris.unito.it/handle/2318/1573112

Vecchione, Loredana, Gambino, Valentina, Raaijmakers, Jonne, Schlicker, Andreas, Fumagalli, Arianna, Russo, Mariangela, Villanueva, Alberto, Beerling, Evelyne, Bartolini, Alice, Mollevi, David G , El-Murr, Nizar, Chiron, Marielle, Calvet, Loreley, Nicolazzi, Céline, Combeau, Cécile, Henry, Christophe, Simon, Iris M , Tian, Sun, In ', T Veld, Sjors, D', Ario, Giovanni, Mainardi, Sara, Beijersbergen, Roderick L , Lieftink, Cor, Linn, Sabine, Rumpf-Kienzl, Cornelia, Delorenzi, Mauro, Wessels, Lodewyk, Salazar, Ramon, Di Nicolantonio, Federica, Bardelli, Alberto, Van Rheenen, Jacco, Medema, René H , Tejpar, Sabine, Bernards, René (2016)
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
https://iris.unito.it/handle/2318/1571012

Sartore-Bianchi, Andrea, Ardini, Elena, Bosotti, Roberta, Amatu, Alessio, Valtorta, Emanuele, Somaschini, Alessio, Raddrizzani, Laura, Palmeri, Laura, Banfi, Patrizia, Bonazzina, Erica, Misale, Sandra, Marrapese, Giovanna, Leone, Antonella, Alzani, Rachele, Luo, David, Hornby, Zachary, Lim, Jonathan, Veronese, Silvio, Vanzulli, Angelo, Bardelli, Alberto, Martignoni, Marcella, Davite, Cristina, Galvani, Arturo, Isacchi, Antonella, Siena, Salvatore (2016)
Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
https://iris.unito.it/handle/2318/1559737

Russo, Mariangela, Bardelli, Alberto (2016)
Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies.
https://iris.unito.it/handle/2318/1622761

Oddo, D, Sennott, Em, Barault, L, Valtorta, E, Arena, S, Cassingena, A, Filiciotto, G, Marzolla, G, Elez, E, van Geel RM,, Bartolini, A, Crisafulli, G, Boscaro, V, Godfrey, Jt, Buscarino, M, Cancelliere, C, Linnebacher, M, Corti, G, Truini, M, Siravegna, G, Grasselli, J, Gallicchio, M, Bernards, R, Schellens, Jh, Tabernero, J, Engelman, Ja, Sartore-Bianchi, A, Bardelli, A, Siena, S, Corcoran, Rb, Di Nicolantonio, F (2016)
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer.
https://iris.unito.it/handle/2318/1569569

Gilles, Maud-Emmanuelle, Maione, Federica, Cossutta, Mélissande, Carpentier, Gilles, Caruana, Laure, Di Maria, Sylvia, Houppe, Claire, Destouches, Damien, Shchors, Ksenya, Prochasson, Christopher, Mongelard, Fabien, Lamba, Simona, Bardelli, Alberto, Bouvet, Philippe, Couvelard, Anne, Courty, José, Giraudo, Enrico, Cascone, Ilaria (2016)
Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature.
https://iris.unito.it/handle/2318/1633736

Conti, Annalisa, Majorini, Maria Teresa, Elliott, Richard, Ashworth, Alan, Lord, Christopher J, Cancelliere, Carlotta, Bardelli, Alberto, Seneci, Pierfausto, Walczak, Henning, Delia, Domenico, Lecis, Daniele (2015)
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
https://iris.unito.it/handle/2318/1559844

Montagut, C, Siravegna, G, Bardelli, A (2015)
Liquid biopsies to evaluate early therapeutic response in colorectal cancer.
https://iris.unito.it/handle/2318/1566487

Kwak, Eunice L , Ahronian, Leanne G , Siravegna, Giulia, Mussolin, Benedetta, Godfrey, Jason T , Clark, Jeffrey W , Blaszkowsky, Lawrence S , Ryan, David P , Lennerz, Jochen K , John Iafrate, A , Bardelli, Alberto, Hong, Theodore S , Corcoran, Ryan B (2015)
Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-Amplified esophagogastric cancer.
https://iris.unito.it/handle/2318/1566550

Alizadeh, Ash A, Aranda, Victoria, Bardelli, Alberto, Blanpain, Cedric, Bock, Christoph, Borowski, Christine, Caldas, Carlos, Califano, Andrea, Doherty, Michael, Elsner, Markus, Esteller, Manel, Fitzgerald, Rebecca, Korbel, Jan O, Lichter, Peter, Mason, Christopher E, Navin, Nicholas, Pe', Er, Dana, Polyak, Kornelia, Roberts, Charles W M, Siu, Lillian, Snyder, Alexandra, Stower, Hannah, Swanton, Charles, Verhaak, Roel G W, Zenklusen, Jean C, Zuber, Johannes, Zucman-Rossi, Jessica (2015)
Toward understanding and exploiting tumor heterogeneity.
https://iris.unito.it/handle/2318/1566488

S Arena, B Bellosillo, G Siravegna, A Martinez, I Canadas, L Lazzari, N Ferruz, M Russo, S Misale, I Gonzalez, M Iglesias, E Gavilan, G Corti, S Hobor, G Crisafulli, M Salido, J Sanchez, A Dalmases, J Bellmunt, G D Fabritiis, A Rovira, F Di Nicolantonio, J Albanell, A Bardelli, C Montagut (2015)
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer.
https://iris.unito.it/handle/2318/1508090

Medico, E, Russo, M, Picco, G, Cancelliere, C, Valtorta, E, Corti, G, Buscarino, M, Isella, C, Lamba, S, Martinoglio, B, Veronese, S, Siena, S, Sartore-Bianchi, A, Beccuti, M, Mottolese, M, Linnebacher, M, Cordero, F, Di Nicolantonio, F, # #co-last and corresponding, Bardelli, A (2015)
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
https://iris.unito.it/handle/2318/1509370

Alamo P, Gallardo A, Di Nicolantonio F, Pavón MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vázquez E, Bardelli A, Céspedes MV, Mangues R (2015)
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
https://iris.unito.it/handle/2318/1506903

Misale, Sandra, Bozic, Ivana, Tong, Jingshan, Peraza-Penton, Ashley, Lallo, Alice, Baldi, Federica, Lin, Kevin H , Truini, Mauro, Trusolino, Livio, Bertotti, Andrea, Di Nicolantonio, Federica, Nowak, Martin A , Zhang, Lin, Wood, Kris C , Bardelli, Alberto (2015)
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.
https://iris.unito.it/handle/2318/1532747

Prahallad, Anirudh, Heynen, Guus J J E , Germano, Giovanni, Willems, Stefan M , Evers, Bastiaan, Vecchione, Loredana, Gambino, Valentina, Lieftink, Cor, Beijersbergen, Roderick L , Di Nicolantonio, Federica, Bardelli, Alberto, Bernards, Rene (2015)
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
https://iris.unito.it/handle/2318/1558698

Siravegna, Giulia, Mussolin, Benedetta, Buscarino, Michela, Corti, Giorgio, Cassingena, Andrea, Crisafulli, Giovanni, Ponzetti, Agostino, Cremolini, Chiara, Amatu, Alessio, Lauricella, Calogero, Lamba, Simona, Hobor, Sebastijan, Avallone, Antonio, Valtorta, Emanuele, Rospo, Giuseppe, Medico, Enzo, Motta, Valentina, Antoniotti, Carlotta, Tatangelo, Fabiana, Bellosillo, Beatriz, Veronese, Silvio, Budillon, Alfredo, Montagut, Clara, Racca, Patrizia, Marsoni, Silvia, Falcone, Alfredo, Corcoran, Ryan B, Di Nicolantonio, Federica, Loupakis, Fotios, Siena, Salvatore, Sartore-Bianchi, Andrea, Bardelli, Alberto (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
https://iris.unito.it/handle/2318/1530472

Barault, L, Amatu, A, Bleeker, F E, Moutinho, C, Falcomatà, C, Fiano, V, Cassingena, A, Siravegna, G, Milione, M, Cassoni, P, De Braud, F, Rudà, R, Soffietti, R, Venesio, T, Bardelli, A, Wesseling, P, de Witt Hamer, P, Pietrantonio, F, Siena, S, Esteller, M, Sartore-Bianchi, A, Di Nicolantonio, F (2015)
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
https://iris.unito.it/handle/2318/1522028

Brian G Blair, Alberto Bardelli, Ben Ho Park (2014)
Somatic alterations as the basis for resistance to targeted therapies.
https://iris.unito.it/handle/2318/142977

A Bardelli, F Di Nicolantonio, S Siena, D Solit (2014)
Kras mutations and resistance to anti-egfr treatment.
https://iris.unito.it/handle/2318/1509374

S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, M Buscarino, L Lazzari, A Sartore-Bianchi, K Bencardino, A Amatu, C Lauricella, E Valtorta, S Siena, F Di Nicolantonio, A Bardelli (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer.
https://iris.unito.it/handle/2318/152225

Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA, Leenstra S, Vandertop WP, Bardelli A, van Noorden CJ, Bleeker FE (2014)
The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
https://iris.unito.it/handle/2318/152056

Angela Esposito, Alberto Bardelli, Carmen Criscitiello, Nicoletta Colombo, Lucia Gelao, Luca Fumagalli, Ida Minchella, Marzia Locatelli, Aron Goldhirsch, Giuseppe Curigliano (2014)
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities.
https://iris.unito.it/handle/2318/145177

Siravegna G, Bardelli A (2014)
Minimal residual disease in breast cancer: in blood veritas.
https://iris.unito.it/handle/2318/152059

Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A (2014)
TGF-? and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.
https://iris.unito.it/handle/2318/153388

C Bettegowda, M Sausen, R J Leary, I Kinde, Y Wang, N Agrawal, B R Bartlett, H Wang, B Luber, R M Alani, E S Antonarakis, N S Azad, A Bardelli, H Brem, J L Cameron, C C Lee, L A Fecher, G L Gallia, P Gibbs, D Le, R L Giuntoli, M Goggins, M D Hogarty, M Holdhoff, S -M Hong, Y Jiao, H H Juhl, J J Kim, G Siravegna, D A Laheru, C Lauricella, M Lim, E J Lipson, S K N Marie, G J Netto, K S Oliner, A Olivi, L Olsson, G J Riggins, A Sartore-Bianchi, K Schmidt, l -M Shih, S M Oba-Shinjo, S Siena, D Theodorescu, J Tie, T T Harkins, S Veronese, T -L Wang, J D Weingart, C L Wolfgang, L D Wood, D Xing, R H Hruban, J Wu, P J Allen, C M Schmidt, M A Choti, V E Velculescu, K W Kinzler, B Vogelstein, N Papadopoulos, L A Diaz (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies.
https://iris.unito.it/handle/2318/152058

Russo M, Di Nicolantonio F, Bardelli A (2014)
Climbing RAS, the Everest of Oncogenes.
https://iris.unito.it/handle/2318/141961

Emily Hannah Crowley, Sabrina Arena, Simona Lamba, Federica Di Nicolantonio, Alberto Bardelli (2014)
Targeted Knock-in of the Polymorphism rs61764370 Does Not Affect KRAS Expression but Reduces let-7 Levels.
https://iris.unito.it/handle/2318/141858

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R (2014)
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
https://iris.unito.it/handle/2318/152041

Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A (2014)
Acquired resistance to EGFR-targeted therapies in colorectal cancer.
https://iris.unito.it/handle/2318/158351

L Barault, A Amatu, F E Bleeker, C Moutinho, A Cassingena, F Tosi, T Venesio, M Esteller, A Bardelli, S Siena, A Sartore-Bianchi, F Di Nicolantonio (2014)
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients.
https://iris.unito.it/handle/2318/1509371

Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A (2014)
Mutational profiling of kinases in glioblastoma.
https://iris.unito.it/handle/2318/152061

Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution.
https://iris.unito.it/handle/2318/154348

Siravegna G, Bardelli A (2014)
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance.
https://iris.unito.it/handle/2318/155720

Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez ME, Tabernero J, Villanueva J (2014)
Circulating pEGFR is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer.
https://iris.unito.it/handle/2318/155794

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3.
https://iris.unito.it/handle/2318/147879

L A Diaz, A Bardelli (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA.
https://iris.unito.it/handle/2318/152055

Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F (2013)
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.
https://iris.unito.it/handle/2318/132493

Di Nicolantonio F, Bardelli A (2013)
Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing?
https://iris.unito.it/handle/2318/130966

Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F (2013)
BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
https://iris.unito.it/handle/2318/140935

V Boscaro, D Zecchin, A Bardelli, F Di Nicolantonio, M Gallicchio (2013)
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening.
https://iris.unito.it/handle/2318/146843

Alessia Bottos, Alberto Bardelli (2013)
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?
https://iris.unito.it/handle/2318/142884

Bardelli A*, Corso S*, Bertotti A*, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S (*Co-First Authors) (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer.
https://iris.unito.it/handle/2318/134432

Emily Crowley, Federica Di Nicolantonio, Fotios Loupakis, Alberto Bardelli (2013)
Liquid biopsy: monitoring cancer-genetics in the blood.
https://iris.unito.it/handle/2318/138263

C Basilico, S Pennacchietti, E Vigna, C Chiriaco, S Arena, A Bardelli, D Valdembri, G Serini, P Michieli (2013)
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET.
https://iris.unito.it/handle/2318/142883

M Martini, M Russo, S Lamba, E Vitiello, E H Crowley, F Sassi, D Romanelli, M Frattini, A Marchetti, A Bardelli (2013)
Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis.
https://iris.unito.it/handle/2318/131744

Zecchin D, Arena S, Martini M, Sassi F, Pisacane A, Di Nicolantonio F, Bardelli A (2013)
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
https://iris.unito.it/handle/2318/126926

Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A (2012)
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.
https://iris.unito.it/handle/2318/129791

Prahallad A*, Sun C*, Huang S*, Di Nicolantonio F*, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (*shared first authorship) (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
https://iris.unito.it/handle/2318/126889

Misale, S, Yaeger, R, Hobor, S, Scala, E, Janakiraman, M, Liska, D, Valtorta, E, Schiavo, R, Buscarino, M, Siravegna, G, Bencardino, K, Cercek, A, Chen, Ct, Veronese, S, Zanon, C, Sartore-Bianchi, A, Gambacorta, M, Gallicchio, M, Vakiani, E, Boscaro, V, Medico, E, Weiser, M, Siena, S, Di Nicolantonio, F, Solit, D, Bardelli, A (2012)
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer.
https://iris.unito.it/handle/2318/131279

Giorgia Migliardi, Francesco Sassi, Davide Torti, Francesco Galimi, Eugenia R Zanella, Michela Buscarino, Dario Ribero, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Mauro Risio, Lorenzo Capussotti, Silvia Marsoni, Federica Di Nicolantonio, Alberto Bardelli, Paolo M Comoglio, Livio Trusolino*, Andrea Bertotti* (*Co-Senior Authors) (2012)
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS.
https://iris.unito.it/handle/2318/107406

Cardone L, Bardelli A, Avvedimento VE (2012)
Activation of ?-Catenin by Oncogenic PIK3CA and EGFR Promotes Resistance to Glucose Deprivation by Inducing a Strong Antioxidant Response.
https://iris.unito.it/handle/2318/103002

Martini M, Vecchione L, Siena S, Tejpar, Bardelli A (2012)
Targeted therapies: how personal should we go?
https://iris.unito.it/handle/2318/105152

Wallin JJ, Guan J, Edgar KA, Zhou W, Francis R, Torres AC, Haverty PM, Eastham-Anderson J, Arena S, Bardelli A, Griffin S, Goodall JE, Grimshaw KM, Hoeflich KP, Torrance C, Belvin M, Friedman LS (2012)
Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes.
https://iris.unito.it/handle/2318/102943

Bardelli A, Jänne PA (2012)
The road to resistance: EGFR mutation and cetuximab.
https://iris.unito.it/handle/2318/93978

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G (2011)
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
https://iris.unito.it/handle/2318/131012

Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C, Francia di Celle P, Chiarle R, Godio L, Pich A, Facchetti F, Ponzoni M, Marmont F, Zanon C, Bardelli A, Inghirami G (2011)
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
https://iris.unito.it/handle/2318/86676

Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A (2011)
KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.
https://iris.unito.it/handle/2318/96347

Valentina Boscaro, Davide Zecchin, Federica Di Nicolantonio, Alberto Bardelli, Margherita Gallicchio (2011)
Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies.
https://iris.unito.it/handle/2318/97860

Molinari F*, Felicioni L*, Buscarino M*, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabisio O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, ? Frattini M? (*Shared first authorship - ?Co-Senior authors) (2011)
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
https://iris.unito.it/handle/2318/93560

Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Garufi C, Bochicchio A, Rosati G, Aprile G, Giaquinta S, Torri V, Bardelli A, Gion M, Martoni A (2011)
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
https://iris.unito.it/handle/2318/132306

Davide Zecchin, Margherita Gallicchio, Valentina Boscaro, Francesco Sassi, Enzo Medico, Federica Di , Nicolantonio, Alberto Bardelli (2011)
Modeling tumor progression and identifying genotype-drug interactions by the sequential introduction of cancer mutations into the genome of human normal cells.
https://iris.unito.it/handle/2318/93906

Yardena Samuels, Alberto Bardelli, Carlos Lopez-Otin (2011)
The Cancer Genome.
https://iris.unito.it/handle/2318/87471

G M Stella, S Benvenuti, D Gramaglia, A Scarpa, A Tomezzoli, P Cassoni, R Senetta, T Venesio, E Pozzi, A Bardelli, P M Comoglio (2011)
MET mutations in cancers of unknown primary origin (CUPs).
https://iris.unito.it/handle/2318/81777

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A?, Trusolino L? (?Co-Senior authors) (2011)
A molecularly annotated platform of patient-derived xenografts (?xenopatients?) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
https://iris.unito.it/handle/2318/96346

Alberto Bardelli, Miriam Martini (2010)
MLK4 gene, a new diagnostic and prognostic marker in cancers.
https://iris.unito.it/handle/2318/82422

Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, Van Noorden CJ (2010)
The prognostic IDH1 ( R132 ) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma.
https://iris.unito.it/handle/2318/132231

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
https://iris.unito.it/handle/2318/131214

Appendino G, Bardelli A (2010)
Broccoli, PTEN deletion and prostate cancer: where is the link?
https://iris.unito.it/handle/2318/131067

Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A (2010)
Isogenic mutant human cells: a new tool for personalized cancer medicine.
https://iris.unito.it/handle/2318/127408

Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S (2010)
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
https://iris.unito.it/handle/2318/132677

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
https://iris.unito.it/handle/2318/127426

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S (2010)
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.
https://iris.unito.it/handle/2318/131170

Corbo V, Ritelli R, Barbi S, Funel N, Campani D, Bardelli A, Scarpa A (2010)
Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.
https://iris.unito.it/handle/2318/131114

Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van', t Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van', t Veer L, Easton DF, Spellman PT, Martin S, Barker AD, Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, Getz G, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, Speed TP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, Hudson TJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, Stratton MR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, Collins FS, Compton CC, DePinho RA, Easton DF, Futreal PA, Gerhard DS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, Yang H (2010)
International network of cancer genome projects.
https://iris.unito.it/handle/2318/132461

Bardelli A, Siena S (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer.
https://iris.unito.it/handle/2318/107891

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F (2010)
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
https://iris.unito.it/handle/2318/79164

Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, Bardelli A, Scarpa A (2010)
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.
https://iris.unito.it/handle/2318/130826

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010)
Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective population-based Consortium analysis.
https://iris.unito.it/handle/2318/79839

De Roock, W, * Jonker, Dj, * Di Nicolantonio, F, * Sartore-Bianchi, A, Tu, D, Siena, S, Lamba, S, Arena, S, Frattini, M, Piessevaux, H, Van Cutsem, E, O', Callaghan, Cj, Khambata-Ford, S, Zalcberg, Jr, Simes, J, Karapetis, Cs, Bardelli, A, Tejpar, S (*co-first authorship) (2010)
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
https://iris.unito.it/handle/2318/130162

Zecchin D, Bardelli A (2010)
Tracking the genomic evolution of breast cancer metastasis.
https://iris.unito.it/handle/2318/70454

Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Håkansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll H, Siena S, Tabernero J, Van Cutsem E (2010)
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
https://iris.unito.it/handle/2318/131811

Sartore-Bianchi A*, Di Nicolantonio F*, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, ^ Siena S^ (*shared first authorship, ^shared last authorship) (2009)
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
https://iris.unito.it/handle/2318/127203

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009)
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer.
https://iris.unito.it/handle/2318/132144

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies.
https://iris.unito.it/handle/2318/132542

Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA (2009)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).
https://iris.unito.it/handle/2318/131261

Bleeker FE, Lamba S, Zanon C, van Tilborg AA, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Bardelli A (2009)
Absence of AKT1 mutations in glioblastoma.
https://iris.unito.it/handle/2318/132678

Flonta SE, Arena S, Pisacane A, Michieli P, Bardelli A (2009)
Expression and Functional Regulation of Myoglobin in Epithelial Cancers.
https://iris.unito.it/handle/2318/131981

Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, Vallacchi V, Scarpa A, Felicioni L, Buck M, Marchetti A, Comoglio PM, Bardelli A, Tamagnone L (2009)
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer.
https://iris.unito.it/handle/2318/113386

Lamba S, Felicioni L, Buttitta F, Bleeker FE, Malatesta S, Corbo V, Scarpa A, Rodolfo M, Knowles M, Frattini M, Marchetti A, Bardelli A (2009)
Mutational profile of GNAQQ209 in human tumors.
https://iris.unito.it/handle/2318/131300

Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A (2009)
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
https://iris.unito.it/handle/2318/131718

Gallicchio M, Di Nicolantonio F, Arena S , Zecchin D, Martini M, Flonta S, Stella G, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A (2009)
EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES.
https://iris.unito.it/handle/2318/94180

Donald William Parsons, Tian-Li Wang, Yardena Samuels, Alberto Bardelli, Christopher Lengauer, Victor Velculescu, Kenneth Kinzler, Bert Vogelstein (2008)
PI3K Pathway Mutations in Cancer.
https://iris.unito.it/handle/2318/75071

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer.
https://iris.unito.it/handle/2318/130776

BARDELLI A, DI NICOLANTONIO F, ARENA S (2008)
ISOGENIC HUMAN CELL LINES COMPRISING MUTATED CANCER ALLELES AND PROCESS USING THE CELL LINES.
https://iris.unito.it/handle/2318/127475

Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A (2008)
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.
https://iris.unito.it/handle/2318/133644

Arena S, Bardelli A (2008)
Understanding how kinase-targeted therapies work.
https://iris.unito.it/handle/2318/46194

Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, Scarpa A, Leenstra S, Frattini M, Barbareschi M, Del Grammastro M, Sciarrotta MG, Zanon C, Marchetti A, Bardelli A (2008)
AKT1 (E17K) in human solid tumours.
https://iris.unito.it/handle/2318/44726

BENVENUTI S, FRATTINI M, ARENA S, ZANON C, PIEROTTI M, BARDELLI A (2008)
PIK3CA cancer mutations display gender and tissue specificity patterns.
https://iris.unito.it/handle/2318/132600

Bardelli A, Di Nicolantonio F, Arena S (2008)
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica.
https://iris.unito.it/handle/2318/65794

Salvatore Siena, Alberto Bardelli (2008)
K-RAS and B-RAF Mutations And Anti-Egfr Antibody Therapy.
https://iris.unito.it/handle/2318/74752

LIEDTKE C, CARDONE L, TORDAI A, YAN K, GOMEZ HL, FIGUREOA LJ, HUBBARD RE, VALERO V, SOUCHON EA, SYMMANS WF, HORTOBAGYI GN, BARDELLI A, PUSZTAI L (2008)
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
https://iris.unito.it/handle/2318/80553

BALAKRISHNAN A, BLEEKER FE, LAMBA S, RODOLFO M, DANIOTTI M, SCARPA A, VAN TILBORG AA, LEENSTRA S, ZANON C, BARDELLI A (2007)
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.
https://iris.unito.it/handle/2318/1948

SILVIA BENVENUTI, ANDREA SARTORE-BIANCHI, FEDERICA DI NICOLANTONIO, CARLO ZANON, MAURO MORONI, SILVIO VERONESE, SALVATORE SIENA, ALBERTO BARDELLI (2007)
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti? Epidermal Growth Factor Receptor Antibody Therapies.
https://iris.unito.it/handle/2318/101154

ARENA S, ISELLA C, MARTINI M, DE MARCO A, MEDICO E, BARDELLI A (2007)
Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers.
https://iris.unito.it/handle/2318/36325

SALETTA F, MATULLO G, MANUGUERRA M, ARENA S, BARDELLI A, VINEIS P (2007)
Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells.
https://iris.unito.it/handle/2318/36498

BLEEKER F E, BARDELLI A (2007)
Genomic landscapes of cancers: prospects for targeted therapies.
https://iris.unito.it/handle/2318/27484

Federica Di Nicolantonio, Sabrina Arena, Margherita Gallicchio, Miriam Martini, Davide Zecchin, Simona Flonta, Giulia Stella, Giovanni Appendino, Roberto Fantozzi, Enzo Medico, Alberto Bardelli (2007)
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds.
https://iris.unito.it/handle/2318/97415

S ARENA, A PISACANE, M MAZZONE, P M COMOGLIO, A BARDELLI (2007)
Genetic targeting of the kinase activity of the Met receptor in cancer cells.
https://iris.unito.it/handle/2318/39852

Salvatore Siena, Mauro Moroni, Alberto Bardelli (2006)
Epidermal Growth Factor Receptor Gene Copy Number.
https://iris.unito.it/handle/2318/74750

Salvatore Siena, Mauro Moroni, Giovanna Marrapese, Andrea Sartore-Bianchi, Silvio Veronese, Marcello Gambacorta, Silvia Benvenuti, Federica Di Nicolantonio, Alberto Bardelli (2006)
Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues.
https://iris.unito.it/handle/2318/74751

F DI NICOLANTONIO, A BARDELLI (2006)
Kinase mutations in cancer: chinks in the enemy's armour?
https://iris.unito.it/handle/2318/39592

S BENVENUTI, S ARENA, A BARDELLI (2005)
Identification of cancer genes by mutational profiling of tumor genomes.
https://iris.unito.it/handle/2318/37738

MORONI M, VERONESE S, BENVENUTI S, MARRAPESE G, SARTORE-BIANCHI A, DI NICOLANTONIO F, GAMBACORTA M, SIENA S, BARDELLI A (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
https://iris.unito.it/handle/2318/31364

FRATTINI M, SIGNORONI S, PILOTTI S, BERTARIO L, BENVENUTI S, ZANON C, BARDELLI A, PIEROTTI MA (2005)
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer.
https://iris.unito.it/handle/2318/31308

BACHMAN KE, SAGER J, CHEONG I, CATTO M, BARDELLI A, PARK BH, VOGELSTEIN B, CAROTTI A, KINZLER KW, LENGAUER C (2005)
Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells.
https://iris.unito.it/handle/2318/31341

PARSONS DW, WANG TL, SAMUELS Y, BARDELLI A, CUMMINS JM, DELONG L, SILLIMAN N, PTAK J, SZABO S, WILLSON JK, MARKOWITZ S, KINZLER KW, VOGELSTEIN B, LENGAUER C, VELCULESCU VE (2005)
Colorectal cancer: mutations in a signalling pathway.
https://iris.unito.it/handle/2318/31340

BARDELLI A, VELCULESCU VE (2005)
Mutational analysis of gene families in human cancer.
https://iris.unito.it/handle/2318/31204

S ARENA, S BENVENUTI, A BARDELLI (2005)
Genetic analysis of the kinome and phosphatome in cancer.
https://iris.unito.it/handle/2318/36412

POLATO F, CODEGONI A, FRUSCIO R, PEREGO P, MANGIONI C, SAHA S, BARDELLI A, BROGGINI M (2005)
PRL-3 phosphatase is implicated in ovarian cancer growth.
https://iris.unito.it/handle/2318/40540

WANG Z, SHEN D, PARSONS DW, A BARDELLI, SAGER J, SZABO S, PTAK J, SILLIMAN, N, PETERS BA, VAN DER HEIJDEN MS, PARMIGIANI G, YAN H, WANG TL, RIGGINS G, POWELL SM, WILLSON JK, MARKOWITZ S, KINZLER KW, VOGELSTEIN B, VELCULESCU VE (2004)
Mutational analysis of the tyrosine phosphatome in colorectal cancers.
https://iris.unito.it/handle/2318/38632

BARDELLI A, PARSONS W, VELCULESCU V, KINZLER KW, VOGELSTEIN B (2004)
Tyrosine Kinome.
https://iris.unito.it/handle/2318/74749

WANG TL, DIAZ LA JR, ROMANS K, A BARDELLI, SAHA S, GALIZIA G, CHOTI M, DONEHOWER R, PARMIGIANI G, SHIH IEM, IACOBUZIO-DONAHUE C, KINZLER KW, VOGELSTEIN, B, LENGAUER C, VELCULESCU VE (2004)
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
https://iris.unito.it/handle/2318/40079

SAGER JA, BENVENUTI S, BARDELLI A (2004)
PRL-3: a phosphatase for metastasis?
https://iris.unito.it/handle/2318/31210

KOHLI M, YU J, SEAMAN C, BARDELLI A, KINZLER KW, VOGELSTEIN B, LENGAUER C, ZHANG L (2004)
SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells.
https://iris.unito.it/handle/2318/40591

SAMUELS Y, WANG Z, BARDELLI A, SILLIMAN N, PTAK J, SZABO S, YAN H, GAZDAR A, POWELL SM, RIGGINS GJ, WILLSON JK, MARKOWITZ S, KINZLER KW, VOGELSTEIN B, VELCULESCU VE (2004)
High frequency of mutations of the PIK3CA gene in human cancers.
https://iris.unito.it/handle/2318/36496

BACHMAN KE, BLAIR BG, BRENNER K, BARDELLI A, ARENA S, ZHOU S, HICKS J, DE MARZO AM, ARGANI P, PARK BH (2004)
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells.
https://iris.unito.it/handle/2318/36495

PARKER BS, ARGANI P, COOK BP, LIANGFENG H, CHARTRAND SD, ZHANG M, SAHA S, BARDELLI A, JIANG Y, ST MARTIN TB, NACHT M, TEICHER BA, KLINGER KW, SUKUMAR S, MADDEN SL (2004)
Alterations in vascular gene expression in invasive breast carcinoma.
https://iris.unito.it/handle/2318/40643

BENTIRES-ALJ M, PAEZ JG, DAVID FS, KEILHACK H, HALMOS B, NAOKI K, MARIS JM, RICHARDSON A, BARDELLI A, SUGARBAKER DJ, RICHARDS WG, DU J, GIRARD L, MINNA JD, LOH ML, FISHER DE, VELCULESCU VE, VOGELSTEIN B, MEYERSON M, SELLERS WR, NEEL BG (2004)
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
https://iris.unito.it/handle/2318/39629

BUCKHAULTS P, ZHANG Z, CHEN YC, WANG TL, ST CROIX B, SAHA S, A BARDELLI, MORIN PJ, POLYAK K, HRUBAN RH, VELCULESCU VE, SHIH IEM (2003)
Identifying tumor origin using a gene expression-based classification map.
https://iris.unito.it/handle/2318/37588

BARDELLI A, SAHA S, SAGER JA, ROMANS KE, XIN B, MARKOWITZ SD, LENGAUER C, VELCULESCU VE, KINZLER KW, VOGELSTEIN B (2003)
PRL-3 expression in metastatic cancers.
https://iris.unito.it/handle/2318/42124

Saurabh Saha, Kenneth Kinzler, Bert Vogelstein, Alberto Bardelli (2003)
A Phosphatase Associated with Metastasis.
https://iris.unito.it/handle/2318/74748

A BARDELLI, PARSONS DW, SILLIMAN N, PTAK J, SZABO S, SAHA S, MARKOWITZ S, WILLSON JK, PARMIGIANI G, KINZLER KW, VOGELSTEIN B, VELCULESCU VE (2003)
Mutational analysis of the tyrosine kinome in colorectal cancers.
https://iris.unito.it/handle/2318/36494

RAJAGOPALAN H, BARDELLI A, LENGAUER C, KINZLER KW, VOGELSTEIN B, VELCULESCU VE (2002)
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.
https://iris.unito.it/handle/2318/31367

SAHA S, A BARDELLI, BUCKHAULTS P, VELCULESCU VE, RAGO C, ST CROIX B, ROMANS KE, CHOTI MA, LENGAUER C, KINZLER KW, VOGELSTEIN B (2001)
A phosphatase associated with metastasis of colorectal cancer.
https://iris.unito.it/handle/2318/40913

LONGATI P, COMOGLIO PM, BARDELLI A (2001)
Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.
https://iris.unito.it/handle/2318/39408

A BARDELLI, CAHILL D, LEDERER G, SPEICHER M, KINZLER K, VOGELSTEIN B, LENGAUER C (2001)
Carcinogen-specific induction of genetic instability.
https://iris.unito.it/handle/2318/41306

GIORDANO S, MAFFÈ A, WILLIAMS T A, ARTIGIANI S, GUAL P, BARDELLI A, BASILICO C, MICHIELI P, P COMOGLIO (2000)
Different point mutations in the met oncogene elicit distinct biological properties.
https://iris.unito.it/handle/2318/40054

A BARDELLI, M L BASILE, E AUDERO, S GIORDANO, S WENNSTROM, S MENARD, P M COMOGLIO, C PONZETTO (1999)
Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
https://iris.unito.it/handle/2318/38630

A BARDELLI, P LONGATI, TA WILLIAMS, S BENVENUTI, P M COMOGLIO (1999)
A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth.
https://iris.unito.it/handle/2318/38212

OLIVERO M, VALENTE G, BARDELLI A, LONGATI P, FERRERO N, CRACCO C, TERRONE C, ROCCA-ROSSETTI S, COMOGLIO PM, DI RENZO MF (1999)
Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
https://iris.unito.it/handle/2318/31334

E VIGNA, D GRAMAGLIA, P LONGATI, A BARDELLI, P M COMOGLIO (1999)
Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
https://iris.unito.it/handle/2318/39944

WILLIAMS TA, LONGATI P, PUGLIESE L, GUAL P, A BARDELLI, MICHIELI P (1999)
MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
https://iris.unito.it/handle/2318/38597

P MICHIELI, C BASILICO, S PENNACCHIETTI, A MAFFE', , L TAMAGNONE, S GIORDANO, A BARDELLI, P M COMOGLIO (1999)
Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
https://iris.unito.it/handle/2318/36446

BARDELLI A , LONGATI P , GRAMAGLIA D , BASILICO C , TAMAGNONE L , GIORDANO S, BALLINARI D , MICHIELI P , P COMOGLIO (1998)
Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.
https://iris.unito.it/handle/2318/1673

VILLA-MORUZZI E, PUNTONI F, BARDELLI A, VIGNA E, DE ROSA S, COMOGLIO PM (1998)
Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met.
https://iris.unito.it/handle/2318/31381

BOCCACCIO C, ANDÒ M, TAMAGNONE L, BARDELLI A, MICHIELI P, BATTISTINI C, COMOGLIO PM (1998)
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway.
https://iris.unito.it/handle/2318/40234

GIORDANO S, BARDELLI A, ZHEN Z, MENARD S, PONZETTO C, COMOGLIO PM (1997)
A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
https://iris.unito.it/handle/2318/38406

BARDELLI A, PUGLIESE L, COMOGLIO PM (1997)
"Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection.
https://iris.unito.it/handle/2318/31318

BARDELLI A, COMOGLIO PM (1997)
Scatter factor receptors are key players in a unique multistep program leading to invasive growth.
https://iris.unito.it/handle/2318/31337

BARDELLI A, LONGATI P, GRAMAGLIA D, STELLA MC, COMOGLIO PM (1997)
Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential.
https://iris.unito.it/handle/2318/31317

BATTISTINI C, GIORDANO P, DE ROSA S, CORRADI F, COMOGLIO P, BARDELLI A (1997)
Peptide Antagonists of Cellular Mitogenesis and Motogenesis and Their Therapeutic Use.
https://iris.unito.it/handle/2318/76128

BESSER D, BARDELLI A, DIDICHENKO S, THELEN M, COMOGLIO P, PONZETTO C, NAGAMINE Y (1997)
Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
https://iris.unito.it/handle/2318/37261

BARDELLI A, LONGATI P, ALBERO D, GORUPPI S, SCHNEIDER C, PONZETTO C, COMOGLIO PM (1996)
HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death.
https://iris.unito.it/handle/2318/41672

BORRELLO M G , ALBERTI L , ARIGHI E , BONGARZONE I , BATTISTINI C , BARDELLI A , PASINI B , PIUTTI C , RIZZETTI M G , MONDELLINI P , RADICE M T , PIEROTTI M A (1996)
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
https://iris.unito.it/handle/2318/42152

C PONZETTO, Z ZHEN, E AUDERO, F MAINA, A BARDELLI, M L BASILE, S GIORDANO, R NARSIMHAN, P COMOGLIO (1996)
Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility.
https://iris.unito.it/handle/2318/42158

NALDINI L, VIGNA E, BARDELLI A, FOLLENZI A, GALIMI F, COMOGLIO PM (1995)
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.
https://iris.unito.it/handle/2318/31207

PELICCI G, GIORDANO S, ZHEN Z, SALCINI AE, LANFRANCONE L, BARDELLI A, PANAYOTOU G, WATERFIELD MD, PONZETTO C, PELICCI PG (1995)
The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein.
https://iris.unito.it/handle/2318/43169

VIGNA E, NALDINI L, TAMAGNONE L, LONGATI P, BARDELLI A, MAINA F, PONZETTO C, COMOGLIO PM (1994)
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.
https://iris.unito.it/handle/2318/31208

BARDELLI A, PONZETTO C, COMOGLIO PM (1994)
Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.
https://iris.unito.it/handle/2318/31296

LONGATI P, BARDELLI A, PONZETTO C, NALDINI L, COMOGLIO PM (1994)
Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).
https://iris.unito.it/handle/2318/42106

PONZETTO C, BARDELLI A, ZHEN Z, MAINA F, DALLA ZONCA P, GIORDANO S, GRAZIANI A, PANAYOTOU G, P COMOGLIO (1994)
A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.
https://iris.unito.it/handle/2318/39630

Ponzetto C, Bardelli A, Maina F, Longati P, Panayotou G, Dhand R, Waterfield MD, Comoglio PM (1993)
A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor.
https://iris.unito.it/handle/2318/107159

BARDELLI A, MAINA F, GOUT I, FRY MJ, WATERFIELD MD, COMOGLIO PM, PONZETTO C (1992)
Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains.
https://iris.unito.it/handle/2318/31245

Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, Birchmeier W, Comoglio PM (1991)
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.
https://iris.unito.it/handle/2318/31247

Corsi di insegnamento

• ADE Impatto della Genomica sulla ricerca biomedica e sulla pratica clinica I anno (MED3467)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Le basi genetico-molecolari delle terapie personalizzate. Responsabile prof Alberto Bardelli
  Programma MD-PhD della Scuola di Medicina
• Scientific Communication (3) (BIO0120C Pds GEN)
  Master Program in Molecular Biotechnology
• TIROCINIO di ONCOLOGIA MOLECOLARE (SME0907)
  Corso di Laurea Magistrale in Biotecnologie Mediche - Classe LM-9
• The Genetic Basis of Cancer (BIO0167B Pds 306-TB)
  Master Program in Molecular Biotechnology

Temi di ricerca

A partire dal 2004 coordina un gruppo di ricerca presso il Dipartimento di Oncologia  (Laboratory of Molecular Oncology, Istituto di Candiolo IRCCS). La ricerca è incentrata sull'identificazione di mutazioni in geni che possano rappresentare validi bersagli terapeutici in tumori umani e sullo sviluppo di terapie mirate contro questo tipo di lesioni molecolari.

Gruppi di ricerca

• Diagnosi e terapia dei tumori del tratto gastro-enterico
• Stratificazione molecolare del paziente oncologico
• Terapie innovative e meccanismi di resistenza

Progetti di ricerca

• Medicina molecolare mirata nel cancro del colon retto

Attività in agenda

Consulta la mia agenda

Ricevimento studenti

Previo appuntamento telefonico e/o e-mail